ClinicalTrials.gg
Active, not recruitingNCT04853251BelvedereUpdated Nov 3, 2026

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

A Phase 4 interventional study of PDS Implant With Ranibizumab 100 mg/ml and LUCENTIS (Ranibizumab Injection) in Neovascular Age-related Macular Degeneration, sponsored by Genentech, Inc.. Active, not recruiting at 40 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 4, Interventional, and Treatment

Updated Nov 3, 2026Now Active, not recruiting12 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
188
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.

Planned enrollment
33rd of 124
188 · median 64
Started
2021
with 3 others
Phase 4
33 of 125
none open now
Registered
116th of 125
by date
Lead sponsor
11 of 125
Genentech, Inc.

Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 33rd largest by planned enrollment of the 124 interventional ones that give a count, is one of 4 that started in 2021, is one of 33 in phase 4, and was the 116th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing ranibizumab in Macular Degeneration, or all of them as a file.
02

Study summary

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Ocular Inclusion Criteria:

  • Diagnosis of nAMD prior to screening as determined by the investigator
  • Difference of \<10% in ECD at screening between the 2 eyes as measured by specular microscopy and determined by the independent reading center
  • Availability of historical visual acuity (VA) data and spectral-domain optical coherence tomography (SD-OCT). Additionally, fluorescein angiography or color fundus photography can both be used to support participant eligibility per protocol at investigator discretion
  • Availability of comprehensive historical anti-vascular endothelial growth factor (VEGF) injection data, including agent administered and date of administration from the time of diagnosis, or for at least 2 years prior to screening if diagnosis was made more than 2 years before screening
  • Response to at least two prior anti-VEGF IVT injections as determined by the investigator based on the following:

    • Overall decrease in nAMD disease activity detected on historical or screening OCT
    • Stable or improved best-corrected visual acuity (BCVA)
  • BCVA of 34 letters (approximate 20/200 Snellen equivalent) or better, using Early Treatment of Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters at screening and enrollment
  • All subtypes of nAMD lesions are permissible
  • nAMD lesions at the time of diagnosis must involve the macula
  • Sufficiently clear ocular media and adequate pupillary dilation to allow for clinical examination and analysis and grading by the central reading center of SD-OCT images

Exclusion criteria

Exclusion Criteria

Prior Ocular Treatment

Study Eye:

  • Prior treatment with external-beam radiation therapy or transpupillary thermotherapy
  • Previous treatment with verteporfin injection (PDT) or IVT injection within 2 years of screening
  • Previous laser (except PDT as stated above) used for age related macular degeneration (AMD) treatment
  • History of corneal transplant
  • History of conjunctival surgery in the superotemporal quadrant
  • History of intraocular inflammation following anti-VEGF injection

Either Eye:

  • Previous PDS implantation
  • Previous intraocular surgery (including cataract surgery) within 6 months of study enrollment
  • Prior vitrectomy surgery, submacular surgery, or other surgical intervention for age-related macular degeneration (AMD)
  • Prior pars plana vitrectomy surgery
  • Previous intraocular device implantation, excluding intraocular lenses
  • History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
  • Prior participation in a clinical trial involving any intravitreal agents that are not approved at time of screening
  • Intraocular laser therapy, including selective laser trabeculoplasty, yttrium-aluminum garnet (YAG), prophylactic peripheral iridotomy within 1 year of screening, or YAG capsulotomy within 3 months of screening
  • Contact lens wear in either eye within 2 months of screening
  • Any prior penetrating ocular trauma
  • Any prior ocular blunt trauma affecting corneal or retinal health in the opinion of the investigator, or any ocular blunt trauma within 6 months of screening
  • History of corneal transplantation, including partial-thickness corneal grafts
  • Prior treatment with brolucizumab
  • Prior treatment with external-beam radiation therapy or brachytherapy
  • History of to ranibizumab or any of Susvimo

Macular Neovascularization Lesion (MNV) Characteristics

Study Eye:

  • Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5-disc area [1.27 square millimeters (mm\^2)] in size
  • Subfoveal fibrosis or subfoveal atrophy

Either Eye:

  • MNV due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia
  • MNV masquerading lesions (e.g., cone dystrophy, adult vitelliform dystrophy, pattern dystrophy)

Current or Historical Ocular Conditions

Study Eye:

  • Retinal pigment epithelial tear
  • Retinal tears or peripheral retinal breaks on depressed fundus exam that are untreated, or treated within the 3 months prior to study enrollment
  • Current vitreous hemorrhage
  • Current or history of retinal detachment
  • Previous violation of the posterior capsule is also an exclusion criterion unless it occurred as a result of YAG laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation
  • Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia or evidence of pathologic myopia on depressed fundus examination
  • Preoperative refractive error that exceeds 8 diopters of myopia, for participants who have undergone prior refractive or cataract surgery
  • Spherical equivalent of the refractive error demonstrating more than 5 diopters of hyperopia
  • Preoperative refractive error that exceeds 5 diopters of hyperopia, for participants who have undergone prior refractive or cataract surgery
  • Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study
  • Scleral pathology in the superotemporal quadrant (e.g., scleral thinning or calcification)
  • Conjunctival pathologies in the superotemporal quadrant
  • History or presence of severe posterior blepharitis, recurrent chalazia or hordeolum, severe dry eye syndrome, or severe allergic conjunctivitis
  • Ectropion, entropion or other impairment of the upper or lower eyelid impacting lid functionality needed to protect the ocular surface from exposure
  • Trichiasis
  • Corneal neuropathy
  • Lagophthalmos or incomplete blink
  • Active or history of facial nerve palsy/paresis

Fellow (Non-Study) Eye:

  • Concurrent or history of PDS implantation

Either Eye:

  • Aphakia or absence of the posterior capsule
  • Any concurrent intraocular condition that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results
  • Corneal ECD ≤1500 cells/mm2 in either eye at screening as determined by the independent reading center
  • Fuchs endothelial corneal dystrophy Grade ≥ 2
  • Previous corneal endothelial cell damage, including from blunt or surgical trauma
  • Any ocular condition that precludes obtaining an analyzable specular microscopy image
  • Active or history of corneal edema
  • Active or history of corneal dystrophies
  • Active or history of iridocorneal endothelial syndrome
  • Active or history of pseudoexfoliation syndrome
  • Active or history of herpetic keratitis or kerato-uveitis
  • Any active or history of uveitis
  • Active intraocular inflammation
  • Active or history of keratitis, scleritis, or endophthalmitis
  • Active ocular or periocular infection
  • Active or history of Sjogren's syndrome or keratoconjunctivitis sicca
  • Active or history of floppy eyelid syndrome
  • Active or history of chronic eye rubbing
  • Active thyroid eye disease

Concurrent Systemic Conditions:

  • History of uncontrolled blood pressure
  • Active or history of diseases such as rheumatoid arthritis, lupus, granulomatosis with polyangiitis (Wegener's)
  • History of stroke within the last 3 months prior to screening
  • Uncontrolled atrial fibrillation within 3 months of screening
  • History of myocardial infarction within the last 3 months prior to screening
  • History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the implant and that might affect interpretation of the results of the study or renders the patient at high risk of treatment complications, in the opinion of the investigator
  • Current active systemic infection
  • Use of any systemic anti-VEGF agents
  • Chronic use of oral corticosteroids
  • Active cancer within 12 months of enrollment except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤ 6 and a stable prostate-specific antigen for > 12 months
  • Previous participation in any non-ocular (systemic) disease studies of drugs within 1 month prior to screening (excluding vitamins and minerals)
  • Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives of the screening visit
  • Requirement for continuous use of any medications or treatments indicated as prohibited therapy
  • Pregnant or breastfeeding, or intention to become pregnant during the study
  • Women of must have a negative urine pregnancy test result within 28 days prior to initiation of study treatment. If the urine pregnancy test is positive, it must be confirmed by a serum pregnancy test
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
188 participants (estimated)

Study arms

  • Experimental
    SUSVIMO

    Participants will have the PDS implant (filled prior to implantation with approximately 20 microlitres \[uL\] of the 100 milligrams/millilitres \[mg/ml\] formulation of ranibizumab \[approximately 2 milligrams (mg) dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their enrollment visit. After the initial fill of the implant with ranibizumab, participants will receive implant refill-exchanges at fixed Q24W intervals.

    Device: PDS Implant With Ranibizumab 100 mg/ml · Drug: LUCENTIS (Ranibizumab Injection)

Interventions

  • DevicePDS Implant With Ranibizumab 100 mg/ml

    Ranibizumab 100 mg/mL will be delivered via PDS

  • Ranibizumab (0.5 mg intravitreal \[IVT\] injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a participant discontinues study treatment, he/she may start receiving IVT ranibizumab injections in the study eye, per investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Percent Change in Corneal Endothelial Cell Density (ECD) From Baseline at Week 48 in the Study Eye as Compared With the Fellow Eye, as Assessed by Specular Microscopy

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Percent Change in Corneal ECD From Baseline at Week 24 in the Study Eye as Compared With the Fellow Eye

    Time frame: Baseline, Week 24

  2. Percent Change in the Coefficient of Variation (CV) of Corneal Endothelial Cell Area From Baseline at Weeks 24 and 48 in the Study Eye as Compared With the Fellow Eye

    Time frame: Baseline, Week 24, Week 48

  3. Percent Change in Hexagonal Cells (HEX) From Baseline at Weeks 24 and 48 in the Study Eye as Compared With the Fellow Eye

    Time frame: Baseline, Week 24, Week 48

  4. Percentage of Participants With Ocular Serious Adverse Events (SAEs) and Severity of SAEs

    Time frame: Day 1 up to approximately Week 52

  5. Percentage of Participants With Ocular Adverse Events of Special Interests (AESIs) and Severity of Ocular AESIs

    Time frame: Day 1 to Week 52

  6. Duration of Ocular AESIs

    Time frame: Day 1 to Week 52

  7. Percentage of Participants With Ocular AESIs During the Postoperative Period

    Time frame: Baseline up to 37 days of initial implantation

  8. Percentage of Participants With Ocular AESIs During the Intermediate Postoperative Period

    Time frame: 38 to 93 days after implantation

  9. Percentage of Participants With Ocular AESIs During the Follow-up Period

    The investigator will follow each adverse event (AE) until the event has resolved to baseline grade or better, the event is assessed as stable by the investigator, the participant is lost to follow-up, or the participant withdraws consent.

    Time frame: Week 52

  10. Percentage of Participants With Adverse Device Effects (ADEs)

    Time frame: Day 1 to Week 52

  11. Number of Participants with Anticipated Serious Adverse Device Effects (ASADEs) and Severity of ASADEs

    Time frame: Day 1 to Week 52

  12. Duration of ASADEs

    Time frame: Day 1 to Week 52

07

Study locations

40 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jul 2027, 67 months after the start.

Of 24 industry-sponsored phase 4 interventional studies under Macular Degeneration, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's planned 67 months is above that.

Counting every sponsor, half of 45 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2021
First posted
Apr 21, 2021
StartActual
Dec 14, 2021
Primary completionEst.
Jul 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 3, 2026
Sites
12 sites removed
Show 12 removed
  • Retina Group of New England · Waterford, United States
  • Ft Lauderdale Eye Institute · Plantation, United States
  • Wolfe Eye Clinic · West Des Moines, United States
  • Retina Associates of Kentucky · Lexington, United States
  • Retina Group of Washington · Chevy Chase, United States
  • Western Carolina Retinal Associate PA · Asheville, United States
  • Tulsa Retina Consultants · Tulsa, United States
  • Mid Atlantic Retina · Philadelphia, United States
  • Palmetto Retina Center · Florence, United States
  • Palmetto Retina Center, LLC · West Columbia, United States
  • Austin Retina Associates · Austin, United States
  • Retina Institute of Virginia · Richmond, United States
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Recruiting→Active, not recruiting
    12 sites removed
    Show 12 removed
    • Retina Group of New England · Waterford, United States
    • Ft Lauderdale Eye Institute · Plantation, United States
    • Wolfe Eye Clinic · West Des Moines, United States
    • Retina Associates of Kentucky · Lexington, United States
    • Retina Group of Washington · Chevy Chase, United States
    • Western Carolina Retinal Associate PA · Asheville, United States
    • Tulsa Retina Consultants · Tulsa, United States
    • Mid Atlantic Retina · Philadelphia, United States
    • Palmetto Retina Center · Florence, United States
    • Palmetto Retina Center, LLC · West Columbia, United States
    • Austin Retina Associates · Austin, United States
    • Retina Institute of Virginia · Richmond, United States
    + 2 other changes: verification date and contact details
  2. Oct 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04853251
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Apr 21, 2021
Start date
Dec 14, 2021
Primary completion
Jul 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion